Brief: Newron Provides Update Following Type A Meeting With The FDA
02/07/2026 16:48
BRIEF-Newron Provides Update Following Type A Meeting With The FDA July 2 (Reuters) - Newron Pharmaceuticals SpA NWRN.S:
NEWRON PROVIDES UPDATE FOLLOWING TYPE A MEETING WITH THE FDA
NEWRON PHARMACEUTICALS SPA - FDA DISCUSSES CHANGES NEEDED TO RE-START ENIGMA-TRS 2 ENROLLMENT IN US
NEWRON PHARMACEUTICALS SPA - TO PROPOSE CHANGES TO ADDRESS FDA CONCERNS
NEWRON PHARMACEUTICALS SPA - ENIGMA-TRS 1 TO ENROLL AT LEAST 600 PATIENTS INTERNATIONALLY
NEWRON PHARMACEUTICALS SPA - TO ANNOUNCE ENIGMA-TRS 1 12-WEEK RESULTS IN QIV 2026
Source text: ID:nBw3VsPN7a
Further company coverage: NWRN.S
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study